和黄医药(00013.HK)治疗肺癌药物新药上市申请已获国家药监局受理并予以优先审评

阿斯达克财经
Jan 02, 2025

和黄医药(00013.HK) 公布,沃瑞沙(ORPATHYS,赛沃替尼/ savolitinib)和泰瑞沙(TAGRISSO ,奥希替尼/ osimertinib)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。沃瑞沙是一种强效、高选择性的口服MET 酪氨酸...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10